SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 26, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2021 financial results before the...
NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indicationsPriority review voucher applied to the NDA submission
...
First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need
FDA approval based on data from the INCREASE clinical...
24 Mar 2021
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Gil Golden, Executive Vice President and Chief Medical Officer...
09 Mar 2021
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 9, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United...
24 Feb 2021
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of...
24 Feb 2021
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2020 financial...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity® Pump for...
28 Jan 2021
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution
A separate study in healthy volunteers demonstrated comparable treprostinil exposure...
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments
Company to host a webcast detailing the INCREASE study results on...
04 Jan 2021
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United...